Interleukin-6 as an enhancer of anti-angiogenic therapy for ovarian clear cell carcinoma

Interleukin-6 as an enhancer of anti-angiogenic therapy for ovarian clear cell carcinoma

Abstract Ovarian clear cell carcinoma (OCCC) is a subtype of epithelial ovarian cancer (EOC) that is associated with elevated interleukin-6 (IL-6) expression, resistance to chemotherapy, and increased mortality. Although bevacizumab (Bev) is a widely used anti-angiogenic agent for EOC, the efficacy...

Full description

Bibliographic Details
Main Authors: Toshiyuki Seki, Nozomu Yanaihara, Jason Solomon Shapiro, Misato Saito, Junya Tabata, Ryo Yokomizo, Daito Noguchi, Takafumi Kuroda, Ayako Kawabata, Jiro Suzuki, Kazuaki Takahashi, Haruka Matsuzawa, Misayo Miyake, Masataka Takenaka, Yasushi Iida, Satoshi Yanagida, Aikou Okamoto
Format: Article
Language:English
Published: Nature Publishing Group 2021-04-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-86913-9

Internet

https://doi.org/10.1038/s41598-021-86913-9

Similar Items